“These results represent a new way of targeting oncogenes that have been refractory to standard treatments,” said senior author of the report William Hahn of Dana-Farber, the Broad Institute, and Harvard Medical School (HMS). “What’s particularly exciting is that this approach is potentially highly specific to cancer cells, and therefore should have little toxicity to normal tissues.”